BioTelemetry (NASDAQ: BEAT) and BG Medicine (OTCMKTS:BGMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Earnings & Valuation

This table compares BioTelemetry and BG Medicine’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioTelemetry $208.33 million 4.32 $53.43 million $1.29 21.55
BG Medicine $1.57 million 0.25 -$5.30 million ($0.74) -0.05

BioTelemetry has higher revenue and earnings than BG Medicine. BG Medicine is trading at a lower price-to-earnings ratio than BioTelemetry, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.2% of BioTelemetry shares are held by institutional investors. 9.6% of BioTelemetry shares are held by insiders. Comparatively, 6.5% of BG Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for BioTelemetry and BG Medicine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioTelemetry 1 0 7 0 2.75
BG Medicine 0 0 0 0 N/A

BioTelemetry currently has a consensus target price of $43.50, suggesting a potential upside of 56.47%. Given BioTelemetry’s higher probable upside, equities analysts clearly believe BioTelemetry is more favorable than BG Medicine.

Risk and Volatility

BioTelemetry has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, BG Medicine has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Profitability

This table compares BioTelemetry and BG Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioTelemetry 16.10% 13.66% 8.44%
BG Medicine N/A N/A N/A

Summary

BioTelemetry beats BG Medicine on 11 of the 12 factors compared between the two stocks.

About BioTelemetry

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

About BG Medicine

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Receive News & Stock Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related stocks with our FREE daily email newsletter.